Gov. Mikie Sherrill told the pharmaceutical drug industry she would tackle rising drug prices by reining in the middlemen — pharmacy benefit managers.

The pharmaceutical industry has expressed strong opposition to the government’s push for drug price reductions, warning that such a policy—combined with rising oil prices, exchange rates, raw material ...

More than 5,000 shelved drug candidates were discontinued for business reasons, not safety ones. A new push aims to match ...

The U.S. Federal Trade Commission is vigilantly monitoring pharmaceutical companies as significant patent cliffs approach, aiming to protect consumers from unfair pricing. Meanwhile, R1 Therapeutics ...

Health Affairs' Jeff Byers welcomes Stacie Dusetzina of Vanderbilt University Medical Center and David Simon of the University of Connecticut back to the pod to the current state of drug prices, how ...

To date, every court that has considered substantive challenges to the Medicare drug price negotiation program has ruled ...

Prime biotech buyout targets such as Revolution Medicines and Ascendis Pharma have recently found themselves in the middle of acquisition rumors—though no deals have panned out so far.

Chinese pharmaceutical companies that as a group chalked up record outbound licensing agreements with international industry giants last year are poised to make further advances in 2026, the chairman ...

And a lot of it has come from the pharmaceutical and medical companies.” Eddie O’Gara is my cousin. The farm he works and lives on is the same one my grandfather, Timothy Shannon, was born on in 1884, ...

“Affordability” is the watchword in American politics today. Inflation is squeezing families, but nothing hits harder than the cost of trying to stay alive. Yet as patients weigh whether they can ...

Research has shown that financial conflicts of interest (COIs) are a common issue in medicine and psychiatry, with a 2020 ...

FIRST ON FOX: Shortly after announcing a strategy to go after deceptive direct-to-consumer advertising by the pharmaceutical industry, Robert F. Kennedy Jr. and the Department of Health and Human ...